Literature DB >> 10989246

Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice.

G Zeppetella1, C A O'Doherty, S Collins.   

Abstract

A prospective survey was undertaken to determine the prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. Of 414 consecutive admissions, 33 patients were confused or too unwell to take part and 136 were pain-free. The remaining 245 reported 404 pains (range 1-5 per patient); of these patients, 218 (89%) had breakthrough pain and identified 361 pains (range 1-5 per patient). Breakthrough pain was classified as somatic (46%) visceral (30%), neuropathic (10%) or mixed etiology (16%). Thirty-eight percent of pains were severe or excruciating. The average number of daily breakthrough pain episodes was 4 [corrected] (range 1-14); 49% occurred suddenly. Most (59%) were unpredictable, and 72% lasted less than 30 minutes. Seventy-five percent of patients were dissatisfied with their pain control. Breakthrough pain is common among patients admitted to our hospice. It is frequent, short lasting, often unpredictable and not necessarily related to chronic pain making treatment difficult.

Entities:  

Mesh:

Year:  2000        PMID: 10989246     DOI: 10.1016/s0885-3924(00)00161-5

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  56 in total

1.  [Safety and efficacy of oral trans-mucosal fentanyl citrate in the long-term treatment of breakthrough pain in oncology patients: the ECODIR study].

Authors:  Vicente Valentín Maganto; Carlos Camps Herrero; Joan Carulla Torrent; Javier Cassinello Espinosa; Javier Dorta Delgado; Carlos Jara Sánchez; José Andrés Moreno Nogueira
Journal:  Clin Transl Oncol       Date:  2005-06       Impact factor: 3.405

Review 2.  Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.

Authors:  Frank Elsner; Giovambattista Zeppetella; Josep Porta-Sales; Ignacio Tagarro
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

3.  [Experiences of cancer patients with breakthrough pain and pharmacological treatments].

Authors:  L Bertram; S Stiel; F Elsner; L Radbruch; A Davies; F Nauck; B Alt-Epping
Journal:  Schmerz       Date:  2010-12       Impact factor: 1.107

4.  Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany.

Authors:  Steffen T Simon; Anna Maria Niemand; Hamid Benalia; Raymond Voltz; Irene J Higginson; Claudia Bausewein
Journal:  J Palliat Med       Date:  2012-10-24       Impact factor: 2.947

5.  Intermittent cancer pain: clinical importance and an updated cancer pain classification.

Authors:  Wael Lasheen; Declan Walsh; Nabeel Sarhill; Mellar Davis
Journal:  Am J Hosp Palliat Care       Date:  2009-12-14       Impact factor: 2.500

Review 6.  Management of breakthrough pain in patients with cancer.

Authors:  Leeroy William; Rod Macleod
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 7.  [Cancer pain therapy].

Authors:  F Nauck
Journal:  Urologe A       Date:  2009-10       Impact factor: 0.639

8.  An examination of adherence to pain medication plans in older cancer patients in hospice care.

Authors:  Sara Sanders; Keela A Herr; Perry G Fine; Catherine Fiala; Xiongwen Tang; Chris Forcucci
Journal:  J Pain Symptom Manage       Date:  2012-07-26       Impact factor: 3.612

Review 9.  The evolution and practice of acute pain medicine.

Authors:  Justin Upp; Michael Kent; Patrick J Tighe
Journal:  Pain Med       Date:  2012-12-13       Impact factor: 3.750

10.  Informal hospice caregiver pain management concerns: a qualitative study.

Authors:  Marjorie Kelley; George Demiris; Huong Nguyen; Debra P Oliver; Elaine Wittenberg-Lyles
Journal:  Palliat Med       Date:  2013-04-23       Impact factor: 4.762

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.